Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28944344 | 0.94 | — | — | |
| SCHEMBL28778024 | 0.89 | — | — | |
| SCHEMBL3831144 | 0.85 | — | — | |
| SCHEMBL28589924 | 0.81 | — | — | |
| SCHEMBL16914222 | 0.81 | — | — | |
| SCHEMBL3831648 | 0.79 | TSHR (0.30) | — | |
| SCHEMBL12989448 | 0.79 | LMNA (0.32) | — | |
| SCHEMBL16914146 | 0.79 | EPHX1 (0.34) | — | |
| SCHEMBL28213446 | 0.76 | KDM4E (0.37) | KDM4E | |
| SCHEMBL26089009 | 0.71 | GAA (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114685453-A | Heterocyclic prolinamide derivatives | 奥瑞恩眼科有限责任公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-109476637-B | Heterocyclic prolinamide derivatives | 奥瑞恩眼科有限责任公司 | 2022-02-01 | — | — | CN | disclosed |
| US-9771378-B2 | Fused morpholinopyrimidines and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| WO-2015109109-A1 | FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. (US) | 2015-07-23 | — | — | WO | disclosed |
| EP-2099447-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | Incyte Corporation (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008064157-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-05-29 | — | — | WO | disclosed |